MabCure, Inc. Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents

Published: Mar 19, 2012

NEW YORK--(BUSINESS WIRE)--MabCure Inc., (OTCBB:MBCI) a leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

Back to news